Seeking Alpha

Shares of Momenta Pharmaceuticals (MNTA) crash 23% immediately after the FDA announces it has...

Shares of Momenta Pharmaceuticals (MNTA) crash 23% immediately after the FDA announces it has approved rival Amphastar Pharmaceuticals to market a generic version of Lovenox - posing a serious threat to MNTA's share of the blood thinner market.
Comments (2)
  • User 312235
    , contributor
    Comments (2) | Send Message
     
    Very strong company, with great pipeline.
    Will bounce back big-time.
    19 Sep 2011, 12:43 PM Reply Like
  • kaalia
    , contributor
    Comments (2) | Send Message
     
    at full capacity 40% share of enoxaparin market. Surely Teva/ Amphastar can take another 40% of the market. I do not see topline share of Sandoz going down, though the royalties to Momenta will come down significantly. But then Momenta is sitting on 300m$ cash and a 300m$ valuation of the cash flow of reduced royalties. In addition a possibility to launch Copaxone generic should enable it to sustain a market cap of approx. 750m$. I conservatively see a target price of 14$/ share in next 3 months.
    20 Sep 2011, 03:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs